ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Dipersio Is Chief Of Oncology At Washington University.

July 14, 2000

Guest Editorial: As Sequestration Becomes More Likely, Health Groups Must Make Themselves Heard

February 22, 2013

In Brief: Jack McShulkis Dies Following Stroke; Congress Gives Final Approval to Appropriations Bill

October 28, 1983

Clinical Trials: Data Manager Falsified NSABP Records On 3 Patients, ORI Says

February 12, 1999

Senate Committee Directs NCI To Conduct Research To Eliminate Barriers To Enrollment On Clinical Trials.

July 6, 2007

Without Advance Directives, Families Prolong Treatment

April 27, 2001